There is no slowdown in sight, says Avid Bioservices CEO, as the company today announces further expansion to support new client projects and optimize its novel CHO-based expression system.
KBI will provide services to ReForm to further develop and validate its biologic formulation platform and in turn, will gain access to ReForm’s proprietary excipient technologies.
NIBRT is embracing continuous bioprocessing says training director John Milne, who told us the method helps improve plant flexibility and could reduce manufacturing costs.
Bluebird Bio and Celgene Corporation are collaborating to make a CAR T-cell therapy for patients with relapsed and refractory multiple myeloma in the US.
PPD has expanded its Middleton, WI-based GMP analytical laboratory, increasing its large molecule development capacity with space for more than 100 new employees.
Shire is sending its employees to the National Institute for Bioprocessing and Research Training prior to opening its biomanufacturing site in Dunboyne, Ireland.
‘Splinter-like’ nanostructures have been developed by researchers in the US to deliver biomolecules straight into patient cells for immune-oncology and gene therapies.
The traditionally small molecule firm was ‘late to the biologics game’, but Sanofi says a mixture of external partnerships and mergers are helping shift focus.
LenioBio will offer cell-free protein expression (CFPE) kits for drug screening through a partnership with DowDuPont, and says it is looking into using the tech for bioprocessing.
A gene-inserting technology that effectively implants large molecules into cells could help modify T-cells from a patient’s immune system, says researcher.
BioDuro has acquired Molecular Response LLC and its translational oncology research platform, which includes a biobank of more than 100,000 viable tumor specimens.
Draper has designed a microfluidic transduction device (MTD) it claims will help CAR T-cell therapy developers lower costs, up efficiency – and potentially bring manufacturing to the patient’s bedside.
A newly approved patent will allow CEL-SCI to explore using cellular delivery to prevent and treat infectious diseases using its LEAPS technology, the firm says.
Xencor and Selexis will extend their strategic partnership with the signing of four commercial license agreements to advance XmAb bispecific antibody drug candidates.
Charles River says increased demand for biologics services prompted its recent Devon Park facility acquisition, bringing its Pennsylvania site count to three
Lonza will combine its cell and gene therapy capabilities through four centres of excellence worldwide, following a number of investments in the space.
The French allogeneic T-cell developer says CRISPR/Cas9 technology is an “easy-to-use and cheap tool” for gene editing and plans to license the patents to others.
Lonza has inked a biologics deal with Denali to make neurodegenerative disease therapies, offering the Californian firm opportunity to have production “on their back doorstep.”
GigaGen has relocated laboratory and office space in San Francisco to boost development of antibody therapeutics for patients with immune dysregulation.
Synpromics will make synthetic promotors for a collaboration with UCL Great Ormond Street Institute of Child Health to develop gene therapies for blood-based disorders.
ABL Europe will provide development, manufacturing and quality control release testing services for SillaJen’s oncolytic virus candidate JX-970 at its facility in Strasbourg.
Vector-based vaccine tech firm Vaccitech has secured £20m ($27.1m) in venture capital with investors Google Ventures, Sequoia China, Neptune Ventures and Oxford Sciences Innovation.
